GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Forward PE Ratio

PuraPharm (HKSE:01498) Forward PE Ratio : 0.00 (As of May. 13, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Forward PE Ratio?

PuraPharm's Forward PE Ratio for today is 0.00.

PuraPharm's PE Ratio without NRI for today is 0.00.

PuraPharm's PE Ratio for today is 0.00.


PuraPharm Forward PE Ratio Historical Data

The historical data trend for PuraPharm's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Forward PE Ratio Chart

PuraPharm Annual Data
Trend 2019-12 2020-10
Forward PE Ratio
18.28 11.49

PuraPharm Semi-Annual Data
Forward PE Ratio

Competitive Comparison of PuraPharm's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where PuraPharm's Forward PE Ratio falls into.



PuraPharm Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


PuraPharm  (HKSE:01498) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


PuraPharm Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of PuraPharm's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm (HKSE:01498) Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines